A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis

NCT03765788 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Giant Cell Arteritis

Interventions

DRUG: Secukinumab 300 mg, s.c.
DRUG: Prednisolone
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals